
T-Therapeutics
Cambridge biotech making T-cell receptor bispecifics; raised a $133m Series B in November 2026.
Last refreshed: 14 November 2026 · Appears in 1 active topic
Can T-cell receptor drugs work in autoimmune disease, where none is approved?
Timeline for T-Therapeutics
Mentioned in: Oyster brings Eli Lilly into $60m round
UK Startups and InnovationRaised a $133m Series B
UK Startups and Innovation: T-Therapeutics raises $133m in Series BBackground
T-Therapeutics, a University of Cambridge spinout, announced a $133m Series B on 5 November 2026. Advent Life Sciences and the British Business Bank co-led it; the Bank put in £15m and takes a board seat. Eli Lilly, Johnson & Johnson Innovation, Samsara BioCapital and M Ventures joined, and Sofinnova Partners returned.
The company builds T-cell receptor bispecifics: molecules that grip a marker on a diseased cell with one Arm and pull in a killer T cell with the other. The money takes two programmes, one in cancer and one in autoimmune disease, towards clinical proof of concept. Neither has been tested in people, and the targets are undisclosed.
Lilly backed Oyster Therapeutics five days later. For the Bank, the board seat goes further than its lead in Microbiotica's round in October.
Who led T-Therapeutics' Series B?
What is T-Therapeutics developing?
How much has T-Therapeutics raised?
Why did Eli Lilly invest in T-Therapeutics?
Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 14 November 2026. Editorial standards.